-
Evobrutinib Lowers MS Relapse Rates Over 2 Years of Use, Trial Data Show
Data from a long-term extension of a Phase 2 trial show oral evobrutinib taken for up to 108 weeks led to sustained reductions in relapse rates. Read more here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.